

CITATION REPORT

List of articles citing

Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group

DOI: 10.1016/s0140-6736(98)08513-4
Lancet, The, 1999, 353, 1568-73.

Source: <https://exaly.com/paper-pdf/30783794/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
684	Differential effect of cimetidine on serum concentrations of carbamazepine and phenytoin. <i>Neurology</i> , 1985 , 35, 562-5	6.5	24
683	Utility of disease modifying antirheumatic drugs in "sawtooth" strategy. A prospective study of early rheumatoid arthritis patients up to 15 years. 1999 , 58, 618-22		16
682	Arthritis drug discovery. 1999 , 17, 726-8		3
681	The treatment of rheumatoid arthritis: a review of recent clinical trials. <i>Current Rheumatology Reports</i> , 1999 , 1, 135-8	4.9	2
680	Early aggressive DMARD therapy: the key to slowing disease progression in rheumatoid arthritis. 1999 , 112, 3-7		23
679	Combination therapy in rheumatoid arthritis. <i>Lancet, The</i> , 1999 , 354, 952	4.0	1
678	Leflunomide: a review of its use in active rheumatoid arthritis. 1999 , 58, 1137-64		99
677	Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: a preventive strategy. 1999 , 131, 768-74		84
676	Bibliography. Current world literature. Clinical therapeutics. <i>Current Opinion in Rheumatology</i> , 2000 , 12, B75-94	5.3	
675	Combination drug therapy retards the development of rheumatoid atlantoaxial subluxations. 2000 , 43, 2397-401		73
674	Arthritis. 2000 , 18, IT12-IT14		
673	reumatoïde artritisReumatoïde artritis: monotherapie of combinatietherapie? Een gerandomiseerd onderzoek. 2000 , 38, 141-142		
672	A new era in rheumatoid arthritis treatment-time to introduce a modified treatment pyramid. 2000 , 93, 757-60		2
671	Current treatment paradigms in rheumatoid arthritis. <i>Rheumatology</i> , 2000 , 39 Suppl 1, 30-5	3.9	44
670	Evaluating patients with arthritis of recent onset: studies in pathogenesis and prognosis. 2000 , 284, 2368-73		17
669	Prediction of disease progression in early rheumatoid arthritis by ICTP, RF and CRP. A comparative 3-year follow-up study. <i>Rheumatology</i> , 2000 , 39, 1009-13	3.9	34
668	Remission and response to early treatment of RA assessed by the Disease Activity Score. BARFOT study group. Better Anti-rheumatic Pharmacotherapy. <i>Rheumatology</i> , 2000 , 39, 1031-6	3.9	55

667	[Treatment of rheumatoid arthritis]. 2000 , 114, 777-83		
666	Intensive treatment of rheumatoid arthritis reduces need for dialysis due to secondary amyloidosis. 2000 , 29, 232-5		13
665	Quality of life measures: use and abuse. 2000 , 14, 663-87		58
664	Tumor necrosis factor-alpha blockade in the treatment of rheumatoid arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2001 , 27, 427-43	2.4	50
663	TNF- β inhibition: The Need for a Tumor Necrosis Factor Thermostat. <i>Mayo Clinic Proceedings</i> , 2001 , 76, 573-575	6.4	8
662	Rheumatoid arthritis. Treatment of early disease. <i>Rheumatic Disease Clinics of North America</i> , 2001 , 27, 405-14, x	2.4	29
661	Pharmacotherapy of rheumatoid arthritis: an overview. 2001 , 62, 92-112		11
660	Value of sonography in diagnosis of rheumatoid arthritis. <i>Lancet, The</i> , 2001 , 357, 1056-7	40	62
659	Rheumatoid arthritis. <i>Lancet, The</i> , 2001 , 358, 903-11	40	1051
658	Combinations of conventional disease-modifying antirheumatic drugs. <i>Rheumatic Disease Clinics of North America</i> , 2001 , 27, 415-26, x	2.4	6
657	Combination therapy with disease modifying anti-rheumatic drugs in rheumatoid arthritis. 2001 , 15, 543-61		9
656	The therapeutic approach of early intervention for rheumatoid arthritis: what is the evidence?. 2001 , 40, 1211-20		89
655	Combination therapy in rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2001 , 13, 177-83	5.3	24
654	Combination therapy in rheumatoid arthritis. 2001 , 23, 165-83		4
653	Combination treatment in autoimmune diseases. Methodology of combination trials. 2001 , 23, 27-33		2
652	[Epidemiological and public health aspects of inflammatory rheumatic systemic diseases]. 2001 , 42, 211-6, 219-22		19
651	Anti-TNF agents for rheumatoid arthritis. 2001 , 51, 201-8		85
650	Early rheumatoid arthritis: can we predict its outcome?. 2001 , 31, 168-80		12

649	Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group. 2001 , 44, 1984-92	227
648	On the organization of an early arthritis clinic. 2001 , 15, 1-15	12
647	How is it best to treat early rheumatoid arthritis patients?. 2001 , 15, 125-37	10
646	How can the risk of long-term consequences of rheumatoid arthritis be reduced?. 2001 , 15, 139-70	21
645	What are the costs to society and the potential benefits from the effective management of early rheumatoid arthritis?. 2001 , 15, 171-85	17
644	The Year in Review: Rheumatology. 2001 , 14, 54-69	
643	Progress in the treatment of rheumatoid arthritis. 2001 , 286, 2787-90	62
642	The national database of the German Collaborative Arthritis Centres: II. Treatment of patients with rheumatoid arthritis. 2001 , 60, 207-13	30
641	Treatment strategy, disease activity, and outcome in four cohorts of patients with early rheumatoid arthritis. 2001 , 60, 453-8	40
640	Western and Chinese antirheumatic drug-induced T cell apoptotic DNA damage uses different caspase cascades and is independent of Fas/Fas ligand interaction. 2001 , 166, 6914-24	48
639	Rescue of combination therapy failures using infliximab, while maintaining the combination or monotherapy with methotrexate: results of an open trial. 2002 , 41, 1109-12	20
638	Drug survival, efficacy and toxicity of monotherapy with a fully human anti-tumour necrosis factor-alpha antibody compared with methotrexate in long-standing rheumatoid arthritis. 2002 , 41, 430-9	46
637	Effective treatment of early rheumatoid arthritis with a combination of methotrexate, prednisolone and cyclosporin. <i>Rheumatology</i> , 2002 , 41, 110-1	3.9 4
636	Analysis of improvements, full responses, remission and toxicity in rheumatoid patients treated with step-up combination therapy (methotrexate, cyclosporin A, sulphasalazine) or monotherapy for three years. 2002 , 41, 892-8	36
635	The effects of disease-modifying anti-rheumatic drugs on the Health Assessment Questionnaire score. Lessons from the leflunomide clinical trials database. 2002 , 41, 899-909	21
634	Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review. 2002 , 41, 1346-56	99
633	Advances in the medical management of rheumatoid arthritis. 2002 , 63, 294-7	4
632	The evolving therapy of rheumatic diseases, the future is now. 2002 , 2, 1-11	2

631	Tumor necrosis factor-alpha blockade: a novel therapy for rheumatic disease. 2002 , 103, 231-42		70
630	Second-line drugs used in recent-onset rheumatoid arthritis in Brittany (France). <i>Joint Bone Spine</i> , 2002 , 69, 37-42	2.9	5
629	COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. 2002 , 46, 347-56		400
628	Treating rheumatoid arthritis early: a window of opportunity?. 2002 , 46, 283-5		194
627	Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. 2002 , 46, 894-8		274
626	Guidelines for the management of rheumatoid arthritis: 2002 Update. 2002 , 46, 328-46		1135
625	Criteria for early rheumatoid arthritis: from Bayes' law revisited to new thoughts on pathogenesis. 2002 , 46, 1155-9		53
624	Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. 2002 , 46, 1164-70		221
623	Cost effectiveness of adding leflunomide to a 5-year strategy of conventional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. 2002 , 47, 655-61		23
622	Methotrexat in der Behandlung der juvenilen idiopathischen Arthritis. 2002 , 150, 452-459		2
621	Analysis of the reasons for DMARD therapy discontinuation in patients with rheumatoid arthritis in the Czech and Slovak republics. <i>Clinical Rheumatology</i> , 2002 , 21, 220-6	3.9	7
620	Traitements de fond utilisés au cours des polyarthrites rhumatoïdes récentes en Bretagne. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2002 , 69, 40-46	0.1	
619	Early rheumatoid arthritis: toward tailor-made therapy. <i>Current Rheumatology Reports</i> , 2003 , 5, 287-93	4.9	4
618	The challenge of following process, damage, and function in patients with rheumatoid arthritis in clinical care. <i>Current Rheumatology Reports</i> , 2003 , 5, 336-40	4.9	
617	Assessment of pain in patients with rheumatic diseases. 2003 , 17, 427-49		25
616	Treatment of early rheumatoid arthritis. 2003 , 17, 791-809		9
615	Pharmacological treatment of established rheumatoid arthritis. 2003 , 17, 811-29		22
614	The benefits of early treatment in rheumatoid arthritis: confounding by indication, and the issue of timing. 2003 , 48, 1-5		66

613	Understanding the window of opportunity concept in early rheumatoid arthritis. 2003 , 48, 1771-4	120
612	[Systemic therapy with glucocorticoids. Treatment of rheumatic diseases]. 2003 , 32, 302-5	0
611	[When do we use which drugs? Procedures for the treatment of rheumatoid arthritis]. 2003 , 32, 405-12	
610	Therapeutic strategies for rheumatoid arthritis. 2003 , 2, 473-88	584
609	Adalimumab - a new TNF-alpha antibody for treatment of inflammatory joint disease. 2003 , 3, 351-60	20
608	Challenges in assessing costs of rheumatoid arthritis. 2003 , 14, 65-72; quiz 73	
607	Long term structural effects of combination therapy in patients with early rheumatoid arthritis: five year follow up of a prospective double blind controlled study. 2003 , 62, 764-6	33
606	Can diagnostic triage by general practitioners or rheumatology nurses improve the positive predictive value of referrals to early arthritis clinics?. 2003 , 42, 763-8	39
605	Osteoarthritis and cardiovascular death. 2003 , 62, 495	2
604	Contribution of patient related differences to multidrug resistance in rheumatoid arthritis. 2003 , 62, 15-9	30
603	. 2003 , 62, 495-c-496	78
602	Methotrexate is the leading DMARD in Finland. 2003 , 62, 494; author reply 494-5	12
601	Authors? reply. 2003 , 62, 495-a-495	78
600	Rheumatoid arthritis in 2003: where are we now with treatment?. 2003 , 62 Suppl 2, ii94-6	20
599	Authors? reply. 2003 , 62, 494-a-495	78
598	New concepts in the treatment of rheumatoid arthritis. 2003 , 54, 197-216	58
597	Radiographic progression in early rheumatoid arthritis: a 12-month randomized controlled study comparing the combination of cyclosporin and methotrexate with methotrexate alone. 2003 , 42, 1545-9	41
596	Sarcoidosis: TB or not TB?. 2003 , 62, 495; author reply 495	1

595	Anti-cytokines and cytokines in the treatment of rheumatoid arthritis. 2003 , 9, 1095-106		49
594	[Evidence-based treatment of methotrexate-resistant rheumatoid arthritis. Combinations of conventional disease-modifying antirheumatic agents]. 2003 , 128, 147-9		0
593	Is there still a role for traditional disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis?. <i>Current Opinion in Rheumatology</i> , 2003 , 15, 185-92	5.3	15
592	Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study. 2004 , 63, 675-80		93
591	Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. 2004 , 43, 906-14		523
590	Radiological outcome after four years of early versus delayed treatment strategy in patients with recent onset rheumatoid arthritis. 2004 , 63, 274-9		100
589	A need for greater reporting of socioeconomic status and race in clinical trials. 2004 , 63, 1700-1		10
588	Patients with rheumatoid arthritis in clinical care. 2004 , 63, 221-5		46
587	Attitudes to early rheumatoid arthritis: changing patterns. Results of a survey. 2004 , 63, 1269-75		40
586	HLA-DR-DQ haplotypes and genotypes in Finnish patients with rheumatoid arthritis. 2004 , 63, 1406-12		41
585	The impact of new biologicals in the treatment of rheumatoid arthritis. 2004 , 43 Suppl 3, iii17-iii23		36
584	Two is better than one? Combination therapy in rheumatoid arthritis. 2004 , 43, 1205-7		11
583	Therapeutic advances in rheumatoid arthritis. 2004 , 7, 62-70		2
582	The use of methotrexate in rheumatoid arthritis. 2004 , 34, 465-83		87
581	Should patients with recent-onset polyarthritis receive aggressive treatment?. <i>Joint Bone Spine</i> , 2004 , 71, 475-80	2.9	23
580	Faut-il traiter de façon agressive une polyarthrite debutante ?. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2004 , 71, 854-859	0.1	
579	Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial. 2004 , 50, 55-62		116
578	Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. 2004 , 50, 380-6		1282

577	Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. 2004 , 50, 709-15		477
576	Markers for type II collagen breakdown predict the effect of disease-modifying treatment on long-term radiographic progression in patients with rheumatoid arthritis. 2004 , 50, 1390-9		71
575	Classifying structural joint damage in rheumatoid arthritis as progressive or nonprogressive using a composite definition of joint radiographic change: a preliminary proposal. 2004 , 50, 1083-96		18
574	Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study. 2004 , 50, 2072-81		170
573	Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. 2004 , 50, 3432-43		948
572	Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappaB, osteoprotegerin, and receptor activator of nuclear factor kappaB ligand. 2004 , 50, 3831-43		104
571	Pursuit of optimal outcomes in rheumatoid arthritis. 2004 , 22, 13-26		13
570	Clinical trials in rheumatic diseases: designs and limitations. <i>Rheumatic Disease Clinics of North America</i> , 2004 , 30, 701-24, v-vi	2.4	17
569	Tratamiento de la artritis reumatoide. 2004 , 204, 273-282		0
568	Rheumatoid arthritis: pathogenic mechanisms and therapeutic targets. 2004 , 1, 289-295		5
567	Therapeutic strategies for rheumatoid arthritis. 2004 , 350, 2591-602		416
566	Evidence for early disease-modifying drugs in rheumatoid arthritis. 2004 , 6, 15-18		5
565	Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. <i>Lancet, The</i> , 2004 , 364, 263-9	40	1016
564	Rheumatoid factor revisited. <i>Current Opinion in Rheumatology</i> , 2004 , 16, 246-53	5.3	154
563	How aggressive should initial therapy for rheumatoid arthritis be? Reply. 2005 , 44, 135-136		
562	Treatment of early rheumatoid arthritis. <i>Therapy: Open Access in Clinical Medicine</i> , 2005 , 2, 659-668		1
561	[Effectiveness of methotrexate for the escape by salazosulfapyridine]. 2005 , 125, 579-82		1
560	[Examination of the escape phenomenon in disease modifying antirheumatic drugs]. 2005 , 125, 293-7		1

559	How to assess early rheumatoid arthritis in daily clinical practice. 2005 , 19, 73-89	10
558	Therapeutic strategies in early rheumatoid arthritis. 2005 , 19, 163-77	55
557	Therapies for rheumatoid arthritis: hope springs eternal. 2005 , 10, 1598-606	20
556	Remission in rheumatoid arthritis: wishful thinking or clinical reality?. 2005 , 35, 185-96	55
555	Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. 2005 , 52, 27-35	45 ¹
554	Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial. 2005 , 52, 36-41	150
553	Patients seen for standard rheumatoid arthritis care have significantly better articular, radiographic, laboratory, and functional status in 2000 than in 1985. 2005 , 52, 1009-19	145
552	Superior efficacy of combination therapy for rheumatoid arthritis: fact or fiction?. 2005 , 52, 2975-83	63
551	Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. 2005 , 52, 3381-90	1009
550	Tumor necrosis factor antagonists and infections: the small print on the price tag. 2005 , 53, 631-5	6
549	How aggressive should initial therapy for rheumatoid arthritis be? The Finnish experience. 2005 , 44, 134-5; author reply 135-6	
548	Will our current success in treating rheumatoid arthritis hinder new drug development? That is the question!!. 2005 , 64, 1529-31	6
547	Monetary value of lost productivity over a five year follow up in early rheumatoid arthritis estimated on the basis of official register data on patients' sickness absence and gross income: experience from the FIN-RACo trial. 2006 , 65, 899-904	52
546	A good response to early DMARD treatment of patients with rheumatoid arthritis in the first year predicts remission during follow up. 2005 , 64, 38-43	49
545	Konventionelle Basistherapie entzündlich rheumatischer Erkrankungen. 2005 , 31, 384-390	
544	Konventionelle Basistherapie entzündlich rheumatischer Erkrankungen. 2005 , 31, 384-390	
543	[Update of early arthritis and early rheumatoid arthritis]. 2005 , 130, 1891-6	3
542	A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal. <i>Rheumatology</i> , 2005 , 44, 1414-21	3.9 102

541	Predictors of productivity loss in early rheumatoid arthritis: a 5 year follow up study. 2005 , 64, 130-3		75
540	Combination treatment strategies in early rheumatoid arthritis. 2005 , 64, 1252-6		10
539	Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. 2005 , 64, 1731-6		218
538	Great expectations of modern RA treatment. 2005 , 64, 1249-51		7
537	Treatment of early rheumatoid arthritis. 2005 , 15, 153-162		2
536	Treatment of Rheumatoid Arthritis in the Elderly. 2005 , 35, 151-154		
535	Efficacy and Toxicity Profile of Methotrexate Chloroquine Combination in Treatment of Active Rheumatoid Arthritis. 2005 , 61, 29-32		1
534	Sulfasalazine. 2005 , 93-132		
533	[Treatment of arthritis of recent onset]. 2005 , 1 Suppl 2, S16-23		1
532	The evidence for early intervention. <i>Rheumatic Disease Clinics of North America</i> , 2005 , 31, 575-89	2.4	20
531	Conventional disease-modifying antirheumatic drugs in early arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2005 , 31, 729-44	2.4	14
530	Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis. 2005 , 65, 661-94		77
529	Sulfasalazine: a review of its use in the management of rheumatoid arthritis. 2005 , 65, 1825-49		121
528	Radiografâ simple y artritis reumatoide. Lectura sistemica de la progresi3n radiol3gica y aplicaciones. 2005 , 6, 103-112		
527	Tratamientos combinados en la artritis reumatoide. 2005 , 6, 151-161		1
526	Has rheumatoid arthritis become a milder disease?. 2005 , 2, 331-336		1
525	Aspects of early arthritis. Traditional DMARD therapy: is it sufficient?. 2006 , 8, 211		7
524	Artritis reumatoide del adulto: tratamiento. 2006 , 39, 1-26		

523	[Antimalarials: an update in rheumatic diseases]. 2006 , 2, 190-201		8
522	EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). 2007 , 66, 34-45		508
521	Abstracts of the 31st Scandinavian congress of rheumatology, Reykjavik, Iceland, 16-19 August 2006. Editors: Helgi Jónsson and Gerður Gröðdal. 2006 , 35, 7-56		15
520	Pharmacological management of transient synovitis. 2006 , 7, 35-46		
519	[Not Available]. 2006 , 2 Suppl 2, S1-8		2
518	Tratamientos en artritis reumatoide precoz. 2006 , 7, 38-46		
517	Early rheumatoid arthritis: pitfalls in diagnosis and review of recent clinical trials. 2006 , 66, 1319-37		11
516	Treatment of rheumatoid arthritis. 2006 , 63, 2451-65		118
515	Biomarkers: Strategies to predict outcome of rheumatoid arthritis. 2006 , 3, 11-16		
514	Treatment of early rheumatoid arthritis in developing countries. Biologics or disease-modifying anti-rheumatic drugs?. 2006 , 60, 688-92		15
513	Polyarthrite rhumatoïde de l'adulte: traitement. 2006 , 1, 1-23		1
512	Present and future of combination therapy of autoimmune diseases. <i>Future Rheumatology</i> , 2006 , 1, 649-655		
511	DMARD combination therapy in rheumatoid arthritis: 5-year follow-up results in a daily practice setting. 2006 , 9, 60-63		4
510	[Activity-score based therapy in rheumatoid arthritis]. <i>Zeitschrift Fur Rheumatologie</i> , 2006 , 65, 124, 126-30		0
509	Classic disease modifying anti-rheumatic drugs (DMARDs) in combination with infliximab. The Finnish experience. <i>Rheumatology International</i> , 2006 , 26, 741-8	3.6	17
508	Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. 2006 , 54, 702-10		336
507	Biological treatment in rheumatic diseases: results from a longitudinal surveillance: adverse events. <i>Rheumatology International</i> , 2006 , 26, 916-22	3.6	18
506	Combination therapy for rheumatoid arthritis in the era of biologics. 2006 , 2, 30-41		13

505	Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. <i>Joint Bone Spine</i> , 2006 , 73, 388-95	2.9	105
504	Treating very early rheumatoid arthritis. 2006 , 20, 849-63		95
503	Measuring process of arthritis care: the Arthritis Foundation's quality indicator set for rheumatoid arthritis. 2006 , 35, 211-37		35
502	Acquired resistance to chloroquine in human CEM T cells is mediated by multidrug resistance-associated protein 1 and provokes high levels of cross-resistance to glucocorticoids. 2006 , 54, 557-68		35
501	Treatment of early seropositive rheumatoid arthritis: doxycycline plus methotrexate versus methotrexate alone. 2006 , 54, 621-7		93
500	Combination treatment with methotrexate, cyclosporine, and intraarticular betamethasone compared with methotrexate and intraarticular betamethasone in early active rheumatoid arthritis: an investigator-initiated, multicenter, randomized, double-blind, parallel-group, placebo-controlled study. 2006 , 54, 1181-9		129
499	Efficacy of combination therapy in rheumatoid arthritis: comment on the review by Smolen et al. 2006 , 54, 2032-4; author reply 2034-5		2
498	Reply. 2006 , 54, 2034-2035		3
497	Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis. 2006 , 54, 2830-9		107
496	Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: A meta-analysis. 2006 , 55, 864-72		344
495	Infliximab for rheumatoid arthritis. 2006 , 2, 193-207		5
494	Polymorphism at position +896 of the toll-like receptor 4 gene interferes with rapid response to treatment in rheumatoid arthritis. 2006 , 65, 1241-3		22
493	Foot and ankle in rheumatoid arthritis. 2006 ,		
492	Duration of rheumatoid arthritis influences the degree of functional improvement in clinical trials. 2006 , 65, 227-33		39
491	Are American College of Rheumatology 50% response criteria superior to 20% criteria in distinguishing active aggressive treatment in rheumatoid arthritis clinical trials reported since 1997? A meta-analysis of discriminant capacities. 2006 , 65, 1602-7		30
490	Low circulating soluble interleukin 2 receptor level predicts rapid response in patients with refractory rheumatoid arthritis treated with infliximab. 2006 , 65, 26-9		13
489	Arthritis and its Treatment. 2006 , 105-132		5
488	Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study. 2007 , 66, 235-41		72

487	Leflunomide in the treatment of rheumatoid arthritis. 2006 , 2, 17-31		7
486	Outcomes associated with early rheumatoid arthritis. 2006 , 6, 495-508		10
485	Pharmacogenomics in the treatment of rheumatoid arthritis: clinical implication and perspective. 2006 , 3, 151-163		
484	Should aggressive therapy for rheumatoid arthritis require early use of weekly low-dose methotrexate, as the first disease-modifying anti-rheumatic drug in most patients?. <i>Rheumatology</i> , 2006 , 45, 497-9	3.9	7
483	Curcumin synergistically potentiates the growth-inhibitory and pro-apoptotic effects of celecoxib in osteoarthritis synovial adherent cells. <i>Rheumatology</i> , 2006 , 45, 171-7	3.9	69
482	Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis. 2008 , 67, 656-63		91
481	Combination versus monotherapy for patients with RA--are initial clinical benefits maintained over time?. 2007 , 3, 602-3		
480	Immune-mediated inflammatory diseases (IMiDs) and biologic therapy: a medical revolution. 2007 , 83, 251-60		199
479	Most people over age 50 in the general population do not meet ACR remission criteria or OMERACT minimal disease activity criteria for rheumatoid arthritis. <i>Rheumatology</i> , 2007 , 46, 1020-3	3.9	40
478	Treating rheumatoid arthritis. 2007 , 335, 56-7		4
477	Rituximab in the treatment of rheumatoid arthritis. 2007 , 3, 17-26		5
476	Reporting of radiographic methods in randomised controlled trials assessing structural outcomes in rheumatoid arthritis. 2007 , 66, 651-7		11
475	Optimal use of methotrexate: the advantages of tight control. 2007 , 66, 1409-10		21
474	Patient preferences for treatment: report from a randomised comparison of treatment strategies in early rheumatoid arthritis (BeSt trial). 2007 , 66, 1227-32		48
473	Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). 2007 , 66, 1443-9		372
472	Utilization and costs of medical services and prescription medications for rheumatoid arthritis among recipients covered by a state Medicaid program: a retrospective, cross-sectional, descriptive, database analysis. 2007 , 29, 2456-67		32
471	Cost of Finnish statutory inpatient rehabilitation and its impact on functional and work capacity of patients with early rheumatoid arthritis: experience from the FIN-RACo trial. 2007 , 36, 270-7		8
470	Combination therapy for rheumatoid arthritis: methotrexate and sulfasalazine together or with other DMARDs. 2007 , 3, 450-8; quiz, following 478		49

469	Intensifying treatment of rheumatoid arthritis with combinations of traditional disease-modifying anti-rheumatic drugs among patients with persistent disease did not reduce the need for large joint surgery. 2007 , 36, 424-7		3
468	Early rheumatoid arthritis. 2007 , 81-82, 97-114		16
467	Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility. 2007 , 66 Suppl 3, iii56-60		80
466	The BeSt way to treat early rheumatoid arthritis?. 2007 , 146, 459-60		5
465	A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. 2007 , 56, 1765-75		193
464	Optimizing the use of traditional DMARD in RA: getting the most out of what we can afford!. 2007 , 10, 3-8		1
463	Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use. 2007 , 37, 99-111		58
462	Kinetic modeling of contrast-enhanced MRI: an automated technique for assessing inflammation in the rheumatoid arthritis wrist. 2007 , 35, 781-95		10
461	Anti-TNF therapy in the treatment of ankylosing spondylitis: the Finnish experience. <i>Clinical Rheumatology</i> , 2007 , 26, 1693-700	3.9	21
460	Etanercept and adalimumab treatment in patients with rheumatoid arthritis and spondyloarthropathies in clinical practice: adverse events and other reasons leading to discontinuation of the treatment. <i>Rheumatology International</i> , 2008 , 28, 261-9	3.6	16
459	Induction of remission in rheumatoid arthritis: criteria and opportunities. <i>Rheumatology International</i> , 2008 , 29, 131-9	3.6	5
458	Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies. 2008 , 58, 1310-7		75
457	How antirheumatic drugs protect joints from damage in rheumatoid arthritis. 2008 , 58, 2936-48		85
456	Disease activity of rheumatoid arthritis during pregnancy: results from a nationwide prospective study. 2008 , 59, 1241-8		346
455	The immunopharmaceutical effects and mechanisms of herb medicine. 2008 , 5, 23-31		66
454	Innate immune response gene expression profiles characterize primary antiphospholipid syndrome. 2008 , 9, 38-46		36
453	Approaches to the treatment of early rheumatoid arthritis with disease-modifying antirheumatic drugs. 2008 , 66, 173-8		29
452	Rheumatology. 2008 , 36, 442-446		

451	Are biologics more effective than classical disease-modifying antirheumatic drugs?. 2008 , 10, 118		12
450	Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. <i>Lancet, The</i> , 2008 , 372, 375-82	40	625
449	COMET results are not stellar. <i>Lancet, The</i> , 2008 , 372, 1807-8; author reply 1808	40	2
448	Treating rheumatoid arthritis the sooner, the better. 2008 , 3, 45-47		
447	Folate supplementation and methotrexate in treatment of rheumatoid arthritis. 2008 , 3, 132-133		
446	The rheumatic causes of elbow instability. 2008 , 24, 79-90		4
445	Infliximab treatment in patients with rheumatoid arthritis and spondyloarthropathies in clinical practice: adverse events and other reasons for discontinuation of treatment. 2008 , 37, 6-12		7
444	Belgian rheumatologists' perception on eligibility of RA patients for anti-TNF treatment matches more closely Dutch rather than Belgian reimbursement criteria. <i>Rheumatology</i> , 2009 , 48, 546-50	3.9	5
443	The evolution of biomarkers in rheumatoid arthritis: from clinical research to clinical care. 2008 , 8, 1773-85		6
442	Combination drug strategy in recent-onset rheumatoid arthritis suppresses collagen I degradation and is associated with retardation of radiological progression. 2008 , 37, 90-3		7
441	Discordant perspectives of rheumatologists and patients on COBRA combination therapy in rheumatoid arthritis. <i>Rheumatology</i> , 2008 , 47, 1571-6	3.9	41
440	COBRA combination therapy in daily practice--getting back to the future. <i>Rheumatology</i> , 2008 , 47, 1-2	3.9	3
439	Aggressive combination therapy with intra-articular glucocorticoid injections and conventional disease-modifying anti-rheumatic drugs in early rheumatoid arthritis: second-year clinical and radiographic results from the CIMESTRA study. 2008 , 67, 815-22		73
438	Treatment-related improvement in physical function varies with duration of rheumatoid arthritis: a pooled analysis of clinical trial results. 2008 , 67, 238-43		58
437	Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. 2008 , 148, 124-34		191
436	Northern highlights in rheumatology. <i>Future Rheumatology</i> , 2008 , 3, 121-126		
435	RAPID3 (Routine Assessment of Patient Index Data 3), a rheumatoid arthritis index without formal joint counts for routine care: proposed severity categories compared to disease activity score and clinical disease activity index categories. <i>Journal of Rheumatology</i> , 2008 , 35, 2136-47	4.1	216
434	Innovative treatment strategies for patients with rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2008 , 20, 287-94	5.3	22

433	Speculations on why early treatment of rheumatoid arthritis is uniquely effective. <i>Journal of Rheumatology</i> , 2008 , 35, 2090-3	4.1	5
432	Long-term use of adalimumab in the treatment of rheumatic diseases. 2009 , 1, 51-68		3
431	Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis. 2009 , 68, 1105-12		100
430	Ultrasonographic evaluation of joint involvement in early rheumatoid arthritis in clinical remission: power Doppler signal predicts short-term relapse. <i>Rheumatology</i> , 2009 , 48, 1092-7	3.9	231
429	Discussion: DMARDs and biologic therapies in the management of inflammatory joint diseases. 2009 , 5, 291-9		6
428	Remission achieved after 2 years treatment with low-dose prednisolone in addition to disease-modifying anti-rheumatic drugs in early rheumatoid arthritis is associated with reduced joint destruction still present after 4 years: an open 2-year continuation study. 2009 , 68, 508-13		66
427	Contemporary treatment principles for early rheumatoid arthritis: a consensus statement. <i>Rheumatology</i> , 2009 , 48, 765-72	3.9	51
426	Quality indicators in rheumatology: valid for whom?. 2009 , 68, 1797-9		5
425	Efficacy of prednisone 1-4 mg/day in patients with rheumatoid arthritis: a randomised, double-blind, placebo controlled withdrawal clinical trial. 2009 , 68, 1715-20		36
424	Aktualisiertes Therapieschema der Rheumatoiden Arthritis. Ergebnisse eines Konsensusprozesses deutscher Rheumatologen 2009. 2009 , 34, 234-239		4
423	Inflammatory arthritis: an overview for primary care physicians. 2009 , 121, 148-62		4
422	TNF alpha inhibition as treatment modality for certain rheumatologic and gastrointestinal diseases. 2009 , 9, 295-314		25
421	Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. 2009 , 68, 1870-7		232
420	Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis. 2009 , 68, 914-21		141
419	Erosive progression is minimal, but erosion healing rare, in patients with rheumatoid arthritis treated with adalimumab. A 1 year investigator-initiated follow-up study using high-resolution computed tomography as the primary outcome measure. 2009 , 68, 1585-90		64
418	Facilitating the use of COBRA combination therapy in early rheumatoid arthritis: a pilot implementation study. <i>Journal of Rheumatology</i> , 2009 , 36, 1380-6	4.1	3
417	Rheumatoid atlantoaxial subluxation can be prevented by intensive use of traditional disease modifying antirheumatic drugs. <i>Journal of Rheumatology</i> , 2009 , 36, 273-8	4.1	37
416	Use of risk stratification to target therapies in patients with recent onset arthritis; design of a prospective randomized multicenter controlled trial. 2009 , 10, 71		30

415	Assessing adequate treatment response in patients with rheumatoid arthritis. 2009 , 31, 1219-31		7
414	Drug management of early rheumatoid arthritis - 2008. 2009 , 23, 93-102		14
413	What have we learnt about the development and progression of early RA from RCTs?. 2009 , 23, 13-24		5
412	Methotrexate: still the anchor drug in RA treatment. <i>Joint Bone Spine</i> , 2009 , 76, 452-4	2.9	24
411	Defining remission in rheumatoid arthritis: results of an initial American College of Rheumatology/European League Against Rheumatism consensus conference. 2009 , 61, 704-10		60
410	The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial. 2009 , 60, 1222-31		61
409	Adalimumab response in patients with early versus established rheumatoid arthritis: DE019 randomized controlled trial subanalysis. <i>Clinical Rheumatology</i> , 2009 , 28, 413-9	3.9	25
408	Optimisation de l'usage du méthotrexate dans la polyarthrite rhumatoïde : analyse systématique de la littérature. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2009 , 76, S22-S29	0.1	3
407	Anti-CD20 antibody rituximab in the treatment of rheumatoid arthritis. 2010 , 106, 13-21		20
406	Cytokines as targets for anti-inflammatory agents. 2009 , 1182, 88-96		8
405	Le méthotrexate est toujours le traitement de référence de la polyarthrite rhumatoïde. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2009 , 76, 819-822	0.1	
404	Treatment of rheumatoid arthritis: state of the art 2009. 2009 , 5, 531-41		170
403	Sensitivity and specificity of the American College of Rheumatology 1987 criteria for the diagnosis of rheumatoid arthritis according to disease duration: a systematic literature review and meta-analysis. 2009 , 68, 1184-91		78
402	Treatment strategies for a patient with rheumatoid arthritis and hepatitis C. 2009 , 10, 579-87		8
401	Randomized controlled trial design in rheumatoid arthritis: the past decade. 2009 , 11, 205		29
400	Guidelines for the use of conventional and newer disease-modifying antirheumatic drugs in elderly patients with rheumatoid arthritis. 2009 , 26, 273-93		19
399	A multi-dimensional health assessment questionnaire (MDHAQ) and routine assessment of patient index data (RAPID3) scores are informative in patients with all rheumatic diseases. <i>Rheumatic Disease Clinics of North America</i> , 2009 , 35, 819-27, x	2.4	30
398	Use of the Stanford Health Assessment Questionnaire in estimation of long-term productivity costs in patients with recent-onset rheumatoid arthritis. 2009 , 38, 96-103		13

397	Contemporary use of disease-modifying drugs in the management of patients with early rheumatoid arthritis in Norway. 2009 , 38, 240-5		7
396	Rituximab therapy in patients with rheumatoid arthritis refractory or with contraindication to anti-tumour necrosis factor drugs: real-life experience in Finnish patients. 2009 , 38, 323-7		10
395	An excellent example of an early arthritis clinic -- what is its clinical value?. <i>Journal of Rheumatology</i> , 2009 , 36, 1355-6	4.1	2
394	I farmaci biologici nel trattamento dell'artrite reumatoide. Focus su etanercept. 2009 , 2, 9-17		
393	DMARD naïve period in treatment of rheumatoid arthritis: a different story. 2009 , 4, 87-88		
392	Rheumatoid arthritis. <i>Lancet, The</i> , 2009 , 373, 659-72	40	696
391	Interferon gamma for idiopathic pulmonary fibrosis. <i>Lancet, The</i> , 2009 , 374, 180-2	40	8
390	Treatment of rheumatoid arthritis: we are getting there. <i>Lancet, The</i> , 2009 , 374, 178-80	40	27
389	Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. <i>Lancet, The</i> , 2009 , 374, 459-66	40	223
388	Rheumatoid arthritis: strategy more important than agent. <i>Lancet, The</i> , 2009 , 374, 430-2	40	20
387	Clinical approaches to early inflammatory arthritis. 2009 , 5, 627-33		6
386	The BeSt story: on strategy trials in rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2009 , 21, 291-8	5.3	26
385	Management of patients with rheumatoid arthritis in Latin America: a consensus position paper from Pan-American League of Associations of Rheumatology and Grupo Latino Americano De Estudio De Artritis Reumatoide. <i>Journal of Clinical Rheumatology</i> , 2009 , 15, 203-10	1.1	31
384	Methotrexate in rheumatoid arthritis: experience and recommendations from the 3E initiative. <i>International Journal of Clinical Rheumatology</i> , 2009 , 4, 239-243	1.5	2
383	Long-term outcomes of rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2009 , 21, 284-90	5.3	29
382	Pharmacogenetics in treatment of rheumatoid arthritis. 2010 , 16, 164-75		26
381	MR imaging of early rheumatoid arthritis. 2010 , 30, 143-63; discussion 163-5		78
380	State-of-the-art: rheumatoid arthritis. 2010 , 69, 1898-906		215

379	Infliximab treatment in patients with rheumatoid arthritis and spondyloarthropathies in one rheumatological center: two years' drug survival. <i>Rheumatology International</i> , 2010 , 30, 1611-20	3.6	1
378	Combination therapy in multiple sclerosis. 2010 , 9, 299-308		91
377	Strategies after the failure of the first anti-tumor necrosis factor alpha agent in rheumatoid arthritis. 2010 , 9, 574-82		36
376	Pharmacotherapy: concepts of pathogenesis and emerging treatments. Challenges in clinical trial design in inflammatory arthritis. 2010 , 24, 457-61		1
375	Pharmacotherapy: concepts of pathogenesis and emerging treatments. Optimising the strategy of care in early rheumatoid arthritis. 2010 , 24, 443-55		11
374	Prevention and cure of rheumatoid arthritis: is it possible?. 2010 , 24, 353-61		8
373	Prediction of response to disease modifying antirheumatic drugs in rheumatoid arthritis. <i>Joint Bone Spine</i> , 2010 , 77, 558-63	2.9	20
372	Evidence for predictive validity of remission on long-term outcome in rheumatoid arthritis: a systematic review. <i>Arthritis Care and Research</i> , 2010 , 62, 108-17	4.7	56
371	RAPID3 (Routine Assessment of Patient Index Data) on an MDHAQ (Multidimensional Health Assessment Questionnaire): agreement with DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) activity categories, scored in five versus more than ninety seconds. <i>Arthritis Care and Research</i> , 2010 , 62, 181-9	4.7	78
370	Similar effects of disease-modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis: meta-analysis of 70 randomized placebo-controlled or drug-controlled studies, including 112 comparisons. 2010 , 62, 2852-63		92
369	Prédiction de la réponse aux traitements de fond antirhumatismaux (DMARD) dans la polyarthrite rhumatoïde. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2010 , 77, 590-595	0.1	
368	Plasma profiles in active systemic juvenile idiopathic arthritis: Biomarkers and biological implications. 2010 , 10, 4415-30		34
367	Pre-admission education in surgical rheumatology nursing: towards greater patient empowerment. 2010 , 19, 2980-8		13
366	The changing face of rheumatoid arthritis: sustained remission for all?. 2010 , 10, 605-11		62
365	[General principles for treatment of early rheumatoid arthritis]. 2010 , 56, 360-2		2
364	Management of Rheumatoid Arthritis. 2010 , 1-16		
363	BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy. <i>Rheumatology</i> , 2010 , 49, 1197-9	3.9	44
362	A systematic comparison of combination DMARD therapy and tumour necrosis inhibitor therapy with methotrexate in patients with early rheumatoid arthritis. <i>Rheumatology</i> , 2010 , 49, 91-8	3.9	49

361	The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis. 2010 , 69, 495-502		117
360	First-line DMARD choice in early rheumatoid arthritis--do prognostic factors play a role?. <i>Rheumatology</i> , 2010 , 49, 1267-71	3.9	15
359	A welcome address for the new criteria. 2010 , 69, 1577-9		1
358	Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. 2010 , 69, 987-94		109
357	Clinical trials: Tight control in early RA pays off in the long run. 2010 , 6, 623-4		4
356	Current view of glucocorticoid co-therapy with DMARDs in rheumatoid arthritis. 2010 , 6, 693-702		86
355	DAS-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis. 2010 , 69, 65-9		136
354	Improving the routine management of rheumatoid arthritis: the value of tight control. <i>Journal of Rheumatology</i> , 2010 , 37, 1570-8	4.1	23
353	Remission in early rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2010 , 37, 1444-53	4.1	53
352	Treatment of rheumatoid arthritis: strategies for achieving optimal outcomes. 2010 , 69, 941-2		9
351	Can we cure rheumatoid arthritis?. 2010 , 71, 486-7		
350	Follow-up standards and treatment targets in rheumatoid arthritis: results of a questionnaire at the EULAR 2008. 2010 , 69, 575-8		36
349	Therapieschema der rheumatoiden Arthritis. Die Dreifachkombination Methotrexat plus Sulfasalazin plus Hydroxychloroquin ist mehr als nur eine Alternative zu Leflunomid. 2010 , 35, 129-131		0
348	Treatment options for rheumatoid arthritis beyond TNF- α inhibitors. 2010 , 3, 663-6		2
347	Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis. 2010 , CD008495		32
346	How should rheumatoid arthritis disease activity be measured today and in the future in clinical care?. <i>Rheumatic Disease Clinics of North America</i> , 2010 , 36, 243-57	2.4	10
345	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. 2010 , 69, 964-75		1210
344	Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. 2010 , 69, 1004-9		121

343	Can disease-modifying anti-rheumatic drugs be discontinued in long-standing rheumatoid arthritis? A 15-year follow-up. 2010 , 39, 12-8		26
342	Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. 2010 , 69, 1010-4		113
341	Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis. 2010 , 11, 163-75		57
340	Autoantibody profiling in patients with very early rheumatoid arthritis: a follow-up study. 2010 , 69, 169-74		44
339	Recent advances in rheumatoid arthritis. 2010 , 86, 243-50		10
338	Golimumab: a new anti-TNF-alpha agent for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. 2010 , 6, 721-33		10
337	Efficacy assessed in follow-ups of clinical trials: methodological conundrum. 2010 , 12, 132		1
336	Remission makes its way to rheumatology. 2010 , 12, 129		5
335	Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial. 2010 , 12, R122		69
334	Treating rheumatoid arthritis to target: recommendations of an international task force. 2010 , 69, 631-7		1300
333	Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis. 2010 , 69, 807-12		77
332	Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future. 2011 , 13 Suppl 1, S4		67
331	The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study. 2011 , 70, 1039-46		129
330	General characteristics of an early arthritis cohort in Argentina. <i>Rheumatology</i> , 2011 , 50, 110-6	3.9	18
329	A decrease in disease activity score (DAS) level is associated with a decrease in health assessment questionnaire (HAQ) score, independent of follow-up duration, during 5 years of tightly controlled treatment: results from the BeSt study. 2011 , 70, 168-71		12
328	American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. 2011 , 70, 404-13		518
327	Shared experiences and best practices in the management of rheumatoid arthritis and Crohn's disease. 2011 , 124, e1-18		5
326	[IL-1Ra: its role in rheumatoid arthritis]. 2004 , 56, 41-5		8

325	Comparative effectiveness research (CER): a summary of AHRQ's CER on therapies for rheumatoid arthritis. 2011 , 17, S19-24		1
324	[Italian consensus on the recommendations about the use of methotrexate for the treatment of rheumatic diseases with a focus on rheumatoid arthritis: results from the "3E initiative"]. 2010 , 62, 34-45		6
323	Management of Rheumatoid Arthritis: Consensus Recommendations From the Turkish League Against Rheumatism. 2011 , 26, 273-294		11
322	[Correlation between radiographic, echographic and MRI changes and rheumatoid arthritis progression]. 2004 , 56, 28-40		1
321	[Outcome predictors in rheumatoid arthritis]. 2004 , 56, 21-7		
320	Managed Care Strategies for Improving Patient Outcomes in Rheumatoid Arthritis. 2011 , 17, 1-29		
319	AHRQ's comparative effectiveness research on premixed insulin analogues for adults with type 2 diabetes: understanding and applying the systematic review findings. 2011 , 17, S3-19		29
318	Treatment strategies in recent onset rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2011 , 23, 241-4	5.3	6
317	Remission: a realistic goal in rheumatoid arthritis?. <i>International Journal of Clinical Rheumatology</i> , 2011 , 6, 643-647	1.5	3
316	Cost-effectiveness of adding magnetic resonance imaging to rheumatoid arthritis management. 2011 , 171, 657-67		8
315	Advances in the development and application of biological therapies for rheumatoid arthritis: review of the latest clinical evidence. 2011 , 1, 557-573		
314	Interpreting clinical trial results for moderate-to-severe rheumatoid arthritis: practical applications for rheumatology healthcare providers. 2011 , 23, 479-92		1
313	Treatment of early rheumatoid arthritis: concepts in management. 2011 , 40, 371-88		30
312	Optimizing methotrexate therapy in rheumatoid arthritis: a systematic literature review. <i>Joint Bone Spine</i> , 2011 , 78, 587-92	2.9	27
311	Use of biologics in rheumatoid arthritis: current and emerging paradigms of care. 2011 , 33, 679-707		185
310	Established rheumatoid arthritis: rationale for best practice: physicians' perspective of how to realise tight control in clinical practice. 2011 , 25, 509-21		14
309	[Combination therapy using methotrexate with DMARDs or biologics--current status]. <i>Zeitschrift Fur Rheumatologie</i> , 2011 , 70, 114-22	1.9	4
308	Treating early rheumatoid arthritis intensively: current UK practice does not reflect guidelines. <i>Clinical Rheumatology</i> , 2011 , 30, 103-6	3.9	8

307	Impact of tight control strategy on rheumatoid arthritis in Sarawak. <i>Clinical Rheumatology</i> , 2011 , 30, 615-21	3.9	1
306	Management of rheumatoid arthritis: consensus recommendations from the Hong Kong Society of Rheumatology. <i>Clinical Rheumatology</i> , 2011 , 30, 303-12	3.9	29
305	The value of early intervention in RA--a window of opportunity. <i>Clinical Rheumatology</i> , 2011 , 30 Suppl 1, S33-9	3.9	56
304	Current smoking status is associated to a non-ACR 50 response in early rheumatoid arthritis. A cohort study. <i>Clinical Rheumatology</i> , 2011 , 30, 1589-93	3.9	29
303	Lag time between onset of symptoms and diagnosis in Venezuelan patients with rheumatoid arthritis. <i>Rheumatology International</i> , 2011 , 31, 657-65	3.6	23
302	Intérêt de la triple association méthotrexate, salazopyrine et hydroxychloroquine dans la polyarthrite rhumatoïde : analyse systématique de la littérature. <i>Revue Du Rhumatisme (Edition Française)</i> , 2011 , 78, S19-S25	0.1	3
301	Reduction of long-term disability in inflammatory polyarthritis by early and persistent suppression of joint inflammation: results from the Norfolk Arthritis Register. <i>Arthritis Care and Research</i> , 2011 , 63, 945-52	4.7	27
300	American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. 2011 , 63, 573-86		520
299	Favorable effect of very early disease-modifying antirheumatic drug treatment on radiographic progression in early inflammatory arthritis: Data from the Étude et Suivi des polyarthrites indifférenciées récentes (study and followup of early undifferentiated polyarthritis). 2011 , 63, 1804-11		67
298	Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study. 2011 , 63, 2865-72		94
297	Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints. 2011 , 63, 3702-11		99
296	Risk of hepatotoxicity with add-on leflunomide in rheumatoid arthritis patients. 2011 , 61, 312-6		14
295	Anti-TNF treatment in rheumatoid arthritis. 2011 , 17, 3141-54		55
294	Identification of a lysosomal pathway that modulates glucocorticoid signaling and the inflammatory response. 2011 , 4, ra44		58
293	Cost-effectiveness of combination nonbiologic disease-modifying antirheumatic drug strategies in patients with early rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2011 , 38, 1593-600	4.1	13
292	Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA. 2011 , 27, 315-25		12
291	A marked decline in the incidence of renal replacement therapy for amyloidosis associated with inflammatory rheumatic diseases - data from nationwide registries in Finland. 2011 , 18, 25-8		40
290	Effectiveness of initial treatment allocation based on expert opinion for prevention of rapid radiographic progression in daily practice of an early RA cohort. 2011 , 70, 634-7		18

289	Later comes earlier, nowadays. <i>Journal of Rheumatology</i> , 2011 , 38, 2287-9	4.1	3
288	Early clinical response to treatment predicts 5-year outcome in RA patients: follow-up results from the CAMERA study. 2011 , 70, 1099-103		33
287	Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial. 2011 , 70, 1605-12		141
286	Trends in treatment strategies and the usage of different disease-modifying anti-rheumatic drugs in early rheumatoid arthritis in Finland. Results from a nationwide register in 2000-2007. 2011 , 40, 16-21		16
285	Early management of newly diagnosed rheumatoid arthritis by Canadian rheumatologists: a national, multicenter, retrospective cohort. <i>Journal of Rheumatology</i> , 2011 , 38, 2342-5	4.1	13
284	Optimal care for early RA patients: the challenge of translating scientific data into clinical practice. <i>Rheumatology</i> , 2011 , 50, 1194-200	3.9	20
283	Methotrexate: optimizing the efficacy in rheumatoid arthritis. 2011 , 3, 151-8		27
282	After treat-to-target: can a targeted ultrasound initiative improve RA outcomes?. 2012 , 71, 799-803		76
281	Abstracts of the 34th Scandinavian Congress of Rheumatology. Copenhagen, Denmark. September 2-5, 2012. 2012 , 126, 1-68		
280	Rheumatoid arthritis: Evidence-based rather than habit-based treatment options. 2012 , 8, 374-6		1
279	Treating to target matrix metalloproteinase 3 normalisation together with disease activity score below 2.6 yields better effects than each alone in rheumatoid arthritis patients: T-4 Study. 2012 , 71, 534-40		29
278	Remission induction therapy with methotrexate and prednisone in patients with early rheumatoid and undifferentiated arthritis (the IMPROVED study). 2012 , 71, 1472-7		70
277	A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry. 2012 , 71, 845-50		119
276	Effect of adherence to European treatment recommendations on early arthritis outcome: data from the ESPOIR cohort. 2012 , 71, 1803-8		23
275	Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. <i>Lancet, The</i> , 2012 , 379, 1712-20	4.0	149
274	Rheumatoid Arthritis and Ankylosing Spondylitis. 2012 , 169-195		
273	Rheumatoid arthritis disease measurement: a new old idea. <i>Rheumatology</i> , 2012 , 51 Suppl 6, vi21-7	3.9	29
272	Initial management of rheumatoid arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2012 , 38, 311-25.2.4		15

271	Beware of the biologicals--hospitals may die: the Rheumatism Foundation Hospital, Heinola, Finland (1951-2010). <i>Clinical Rheumatology</i> , 2012 , 31, 1151-4	3.9	3
270	Evaluation of disease activity in rheumatoid arthritis by Routine Assessment of Patient Index Data 3 (RAPID3) and its correlation to Disease Activity Score 28 (DAS28) and Clinical Disease Activity Index (CDAI): an Indian experience. <i>Clinical Rheumatology</i> , 2012 , 31, 1663-9	3.9	18
269	Treatment of early undifferentiated arthritis. 2012 , 7, 215-220		
268	Tight disease control in early RA. <i>Rheumatic Disease Clinics of North America</i> , 2012 , 38, 327-43	2.4	10
267	Anti-inflammatory and antioxidative effects of mucilage of <i>Trigonella foenum graecum</i> (Fenugreek) on adjuvant induced arthritic rats. 2012 , 12, 205-11		74
266	Do rheumatoid arthritis patients have equal access to treatment with new medicines?: tumour necrosis factor-alpha inhibitors use in four European countries. 2012 , 104, 76-83		25
265	A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. 2012 , 64, 2824-35		271
264	Evolution of treatment for rheumatoid arthritis. <i>Rheumatology</i> , 2012 , 51 Suppl 6, vi28-36	3.9	96
263	Impact of socioeconomic gradients within and between countries on health of patients with rheumatoid arthritis (RA): lessons from QUEST RA. 2012 , 26, 705-20		14
262	Évaluation de l'impact des recommandations de la Haute Autorité de santé sur la prise en charge thérapeutique de la polyarthrite rhumatoïde en pratique courante. <i>Revue Du Rhumatisme (Edition Française)</i> , 2012 , 79, 517-522	0.1	
261	My treatment approach to rheumatoid arthritis. <i>Mayo Clinic Proceedings</i> , 2012 , 87, 659-73	6.4	73
260	Midterm clinico-radiologic findings of an open label observation study of add-on tacrolimus with biologics or non-biologic DMARDs. <i>Rheumatology International</i> , 2012 , 32, 3487-94	3.6	3
259	Treatment strategies in early rheumatoid arthritis and prevention of rheumatoid arthritis. <i>Current Rheumatology Reports</i> , 2012 , 14, 472-80	4.9	60
258	Summary of AHRQ's comparative effectiveness review of drug therapy for rheumatoid arthritis (RA) in adults--an update. 2012 , 18, S1-18		23
257	Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study. 2012 , 71, 198-205		108
256	Prescribing practices in a US cohort of rheumatoid arthritis patients before and after publication of the American College of Rheumatology treatment recommendations. 2012 , 64, 630-8		55
255	Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs?. 2013 , 11, 17		50
254	PROMs in inflammatory arthritis: moving from static to dynamic. <i>Clinical Rheumatology</i> , 2013 , 32, 735-43	3.9	27

253	Correlation of 18F-FDG PET/CT assessments with disease activity and markers of inflammation in patients with early rheumatoid arthritis following the initiation of combination therapy with triple oral antirheumatic drugs. 2013 , 40, 403-10		49
252	Response to glucocorticoids at 2 weeks predicts the effectiveness of DMARD induction therapy at 3 months: post hoc analyses from the tREACH study. 2013 , 72, 1659-63		14
251	The effect of the Arthritis Self-Management Program on outcome in African Americans with rheumatoid arthritis served by a public hospital. <i>Clinical Rheumatology</i> , 2013 , 32, 49-59	3.9	14
250	Guidelines for the drug treatment of rheumatoid arthritis. 2013 , 53, 158-183		1
249	Diretrizes para o tratamento da artrite reumatoide. 2013 , 53, 158-183		16
248	Effects of disease modifying anti-rheumatic drugs on subclinical atherosclerosis and endothelial dysfunction which has been detected in early rheumatoid arthritis: 1-year follow-up study. 2013 , 43, 48-54		31
247	Artritis reumatoide (II). 2013 , 11, 1850-1855		
246	Diagnostic et prise en charge thérapeutique de la polyarthrite rhumatoïde en Rhône-Alpes: une enquête « vraie vie » en 2010. <i>Revue Du Rhumatisme (Edition Française)</i> , 2013 , 80, 130-135	0.1	1
245	What is the best treatment strategy for early RA?. 2013 , 27, 523-36		6
244	Creative trial design in RA: optimizing patient outcomes. 2013 , 9, 183-94		12
243	Decline of mean initial prednisone dosage from 10.3 to 3.6 mg/day to treat rheumatoid arthritis between 1980 and 2004 in one clinical setting, with long-term effectiveness of dosages less than 5 mg/day. <i>Arthritis Care and Research</i> , 2013 , 65, 729-36	4.7	29
242	Validation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis: results from a two-year randomized, double-blind trial. 2013 , 65, 1985-94		53
241	The JAK inhibitor tofacitinib for active rheumatoid arthritis: results from Phase III trials. <i>International Journal of Clinical Rheumatology</i> , 2013 , 8, 315-326	1.5	3
240	Trajectory of intensive treat-to-target disease modifying drug regimen in an observational study of an early rheumatoid arthritis cohort. 2013 , 3,		8
239	A prediction rule for the development of arthritis in seropositive arthralgia patients. 2013 , 72, 1920-6		145
238	To what extent is NICE guidance on the management of rheumatoid arthritis in adults being implemented in clinical practice? A regional survey. 2013 , 13, 42-6		6
237	Documenting the value of care for rheumatoid arthritis, analogous to hypertension, diabetes, and hyperlipidemia: is control of individual patient self-report measures of global estimate and physical function more valuable than laboratory tests, radiographs, indices, or remission criteria?. <i>Journal of Rheumatology</i> 2013 , 40, 1469-74	4.1	3
236	Safety and effectiveness of 6 months' etanercept monotherapy and combination therapy in Japanese patients with rheumatoid arthritis: effect of concomitant disease-modifying antirheumatic drugs. <i>Journal of Rheumatology</i> , 2013 , 40, 1658-68	4.1	10

235	Current immunotherapy in rheumatoid arthritis. 2013 , 5, 955-74		79
234	Rheumatoid arthritis. Triple therapy or etanercept after methotrexate failure in RA?. 2013 , 9, 510-2		3
233	Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial. 2013 , 72, 72-8		93
232	The decline in joint replacement surgery in rheumatoid arthritis is associated with a concomitant increase in the intensity of anti-rheumatic therapy: a nationwide register-based study from 1995 through 2010. 2013 , 84, 331-7		69
231	Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study). 2013 , 72, 851-7		65
230	Pharmacokinetic consideration of synthetic DMARDs in rheumatoid arthritis. 2013 , 9, 969-81		
229	Meta-analysis suggests that intensive non-biological combination therapy with step-down prednisolone (COBRA strategy) may also 'disconnect' disease activity and damage in rheumatoid arthritis. 2013 , 72, 406-9		18
228	Changing sulphasalazine to methotrexate does not improve the 2-year outcomes of the initial single DMARD treatment in early rheumatoid arthritis: subanalysis of the FIN-RACo trial. 2013 , 72, 786-8		1
227	Decline in work disability caused by early rheumatoid arthritis: results from a nationwide Finnish register, 2000-8. 2013 , 72, 672-7		24
226	Combination therapy in rheumatoid arthritis: always the best option?. <i>International Journal of Clinical Rheumatology</i> , 2013 , 8, 501-506	1.5	
225	Biomarkers predicting a need for intensive treatment in patients with early arthritis. 2015 , 21, 170-81		18
224	A nationwide cross-sectional overview of patients with rheumatoid arthritis followed in outpatient specialty clinics in Finland. 2014 , 43, 286-90		4
223	Failure in longterm treatment is rare in actively treated patients with rheumatoid arthritis, but may be predicted by high health assessment score at baseline and by residual disease activity at 3 and 6 months: the 5-year followup results of the randomized clinical NEO-RACo trial. <i>Journal of Rheumatology</i> , 2014 , 41, 2379-85	4.1	3
222	Review: treat to target in rheumatoid arthritis: fact, fiction, or hypothesis?. 2014 , 66, 775-82		98
221	Hand and foot surgery rates in rheumatoid arthritis have declined from 1986 to 2011, but large-joint replacement rates remain unchanged: results from two UK inception cohorts. 2014 , 66, 1081-9		83
220	HLA-B*13:01 is associated with salazosulfapyridine-induced drug rash with eosinophilia and systemic symptoms in Chinese Han population. 2014 , 15, 1461-9		30
219	Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial. 2014 , 73, 654-61		84
218	Five-year outcomes of probable rheumatoid arthritis treated with methotrexate or placebo during the first year (the PROMPT study). 2014 , 73, 396-400		32

217	Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritis. 2014 , 16, 430		5
216	Randomised controlled trial of tumour necrosis factor inhibitors against combination intensive therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews. <i>Health Technology Assessment</i> , 2014 , 18, i-xix, 1-164	4.4	17
215	Can we improve the performance and reporting of investigator-initiated clinical trials? Rheumatoid arthritis as an example. 2014 , 73, 1755-60		10
214	Biological treatment in rheumatoid arthritis: when to stop?. <i>Lancet, The</i> , 2014 , 383, 288-9	4.0	6
213	Two-year clinical and radiologic follow-up of early RA patients treated with initial step up monotherapy or initial step down therapy with glucocorticoids, followed by a tight control approach: lessons from a cohort study in daily practice. <i>Clinical Rheumatology</i> , 2014 , 33, 125-30	3.9	15
212	MR and CEUS monitoring of patients with severe rheumatoid arthritis treated with biological agents: a preliminary study. 2014 , 119, 422-31		6
211	Early start and stop of biologics: has the time come?. 2014 , 12, 25		20
210	Treatment of Autoimmune Disease: Established Therapies. 2014 , 1209-1220		
209	Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. 2014 , 73, 958-67		388
208	Therapeutic options after treatment failure in rheumatoid arthritis or spondyloarthritis. 2014 , 31, 780-802		1
207	Triple therapy in rheumatoid arthritis. 2014 , 10, 275-7		4
206	A non-inferiority trial of an attenuated combination strategy ('COBRA-light') compared to the original COBRA strategy: clinical results after 26 weeks. 2014 , 73, 1071-8		74
205	Triple therapy in rheumatoid arthritis. 2014 , 10, 275-277		
204	Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial. 2014 , 73, 1331-9		84
203	Randomized controlled trial comparing 2 different starting doses of methotrexate in rheumatoid arthritis. 2014 , 36, 1005-15		6
202	A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study. 2014 , 73, 1356-61		70
201	Synergistic co-delivery of doxorubicin and paclitaxel by porous PLGA microspheres for pulmonary inhalation treatment. 2014 , 88, 1086-93		81
200	The surgical treatment of rheumatoid arthritis: a new era?. 2014 , 96-B, 1287-9		5

199	Searching for synergy in silico, in vitro and in vivo. 2014 , 1, 30-43		22
198	Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long-term outcomes in early rheumatoid arthritis regardless of initial infliximab. The 5-year follow-up results of a randomised clinical trial, the NEO-RACo trial. 2014 , 73, 1954-61		31
197	Physicians' adherence to tight control treatment strategy and combination DMARD therapy are additively important for reaching remission and maintaining working ability in early rheumatoid arthritis: a subanalysis of the FIN-RACo trial. 2014 , 73, 788-90		14
196	Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. <i>Lancet, The</i> , 2014 , 383, 321-32	40	196
195	When and for how long should glucocorticoids be used in rheumatoid arthritis? International guidelines and recommendations. 2014 , 1318, 32-40		20
194	Tofacitinib versus methotrexate in rheumatoid arthritis. 2014 , 370, 2377-86		495
193	Infliximab, methotrexate and their combination for the treatment of rheumatoid arthritis: a systematic review and meta-analysis. 2015 , 55, 146-158		
192	Fructose 1,6-bisphosphate, a high-energy intermediate of glycolysis, attenuates experimental arthritis by activating anti-inflammatory adenosinergic pathway. <i>Scientific Reports</i> , 2015 , 5, 15171	4.9	37
191	Safety and retention of combination triple disease-modifying anti-rheumatic drugs in new-onset rheumatoid arthritis. 2015 , 45, 1266-73		11
190	Mitigating infection risk with immunotherapy for rheumatoid arthritis. <i>International Journal of Clinical Rheumatology</i> , 2015 , 10, 177-193	1.5	4
189	A Prospective Double Blind Placebo Controlled Trial of Combination Disease Modifying Antirheumatic Drugs vs. Monotherapy (Sulfasalazine) in Patients with Inflammatory Low Backache in Ankylosing Spondylitis and Undifferentiated Spondyloarthritis. 2015 , s1,		1
188	Atlas of Rheumatoid Arthritis. 2015 ,		2
187	[Intra-articular injection of cortisone]. <i>Zeitschrift Fur Rheumatologie</i> , 2015 , 74, 774-9	1.9	1
186	Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. <i>Rheumatology</i> , 2015 , 54, 1200-9	3.9	48
185	The impact of C677T and A1298C MTHFR polymorphisms on methotrexate therapeutic response in East Bohemian region rheumatoid arthritis patients. <i>Rheumatology International</i> , 2015 , 35, 1149-61	3.6	15
184	Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression. 2015 , 27, 211-22		548
183	Infliximab, methotrexate and their combination for the treatment of rheumatoid arthritis: a systematic review and meta-analysis. 2015 , 55, 146-58		6
182	Advances in the management of rheumatoid arthritis. 2015 , 60, 108-14		3

181	Research on Susceptible Genes and Immunological Pathogenesis of Cutaneous Adverse Drug Reactions in Chinese Hans. 2015 , 17, 29-31			10
180	Early rheumatoid arthritis. 2015 , 37-68			
179	Factors Associated With Sustained Remission in Patients With Rheumatoid Arthritis. 2015 , 11, 237-241			
178	Daily practice feasibility and effectiveness of treating long-standing rheumatoid arthritis to target with synthetic disease-modifying antirheumatic drugs: a prospective cohort study. <i>Clinical Rheumatology</i> , 2015 , 34, 1781-5	3.9		9
177	Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trial. 2015 , 17, 97			32
176	Long-term real-life experience with rituximab in adult Finnish patients with rheumatoid arthritis refractory or with contraindication to anti-tumor necrosis factor drugs. <i>Journal of Clinical Rheumatology</i> , 2015 , 21, 24-30	1.1		9
175	Combination conventional DMARDs compared to biologicals: what is the evidence?. <i>Current Opinion in Rheumatology</i> , 2015 , 27, 183-8	5.3		8
174	Key findings from studies of methotrexate tapering and withdrawal in rheumatoid arthritis. 2015 , 8, 751-60			12
173	Rheumatoid Arthritis in the 21st Century: Treatment Patterns and Disease Activity States. <i>Journal of Rheumatology</i> , 2015 , 42, 1542-4	4.1		0
172	2014 Update of the Consensus Statement of the Spanish Society of Rheumatology on the Use of Biological Therapies in Rheumatoid Arthritis. 2015 , 11, 279-294			3
171	Rheumatoid arthritis treatment: the earlier the better to prevent joint damage. <i>RMD Open</i> , 2015 , 1, e000057	9.5		68
170	The past versus the present, 1980-2004: reduction of mean initial low-dose, long-term glucocorticoid therapy in rheumatoid arthritis from 10.3 to 3.6 mg/day, concomitant with early methotrexate, with long-term effectiveness and safety of less than 5 mg/day. 2015 , 22, 89-103			11
169	Total glucosides of paeony can reduce the hepatotoxicity caused by Methotrexate and Leflunomide combination treatment of active rheumatoid arthritis. 2015 , 28, 802-7			31
168	The optimal combination therapy for the treatment of early rheumatoid arthritis. 2015 , 16, 1615-25			9
167	2014 update of the Consensus Statement of the Spanish Society of Rheumatology on the use of biological therapies in rheumatoid arthritis. 2015 , 11, 279-94			60
166	Impact of physicians' adherence to treat-to-target strategy on outcomes in early rheumatoid arthritis in the NEO-RACo trial. 2015 , 44, 449-55			13
165	Ten years of change in clinical disease status and treatment in rheumatoid arthritis: results based on standardized monitoring of patients in an ordinary outpatient clinic in southern Norway. 2015 , 17, 219			37
164	Factors associated with sustained remission in patients with rheumatoid arthritis. 2015 , 11, 237-41			4

163	Clinical and Radiographic Outcomes in Patients Diagnosed with Early Rheumatoid Arthritis in the First Years of the Biologic Treatment Era: A 10-year Prospective Observational Study. <i>Journal of Rheumatology</i> , 2015 , 42, 2279-87	4.1	24
162	Treatment of rheumatoid arthritis with methotrexate alone and in combination with other conventional DMARDs using the T2T strategy. A cohort study. <i>Clinical Rheumatology</i> , 2015 , 34, 215-20	3.9	17
161	Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial. 2015 , 74, 27-34		82
160	Rheumatic Diseases. 2015 , 27-51		
159	Prevalence of MTX Intolerance in Rheumatoid Arthritis- A 3 Year Prospective Hospital Based Study. 2016 , 6,		
158	STAT6 and STAT1 Pathway Activation in Circulating Lymphocytes and Monocytes as Predictor of Treatment Response in Rheumatoid Arthritis. <i>PLoS ONE</i> , 2016 , 11, e0167975	3.7	10
157	Tumor Necrosis Factor, but Not Neutrophils, Alters the Metabolic Profile in Acute Experimental Arthritis. <i>PLoS ONE</i> , 2016 , 11, e0146403	3.7	8
156	Tapering conventional synthetic DMARDs in patients with early arthritis in sustained remission: 2-year follow-up of the tREACH trial. 2016 , 75, 2119-2123		24
155	Targeting ultrasound remission in early rheumatoid arthritis: the results of the TaSER study, a randomised clinical trial. 2016 , 75, 1043-50		129
154	Predictive factors of radiological progression after 2 years of remission-steered treatment in early arthritis patients: a post hoc analysis of the IMPROVED study. <i>RMD Open</i> , 2016 , 2, e000172	5.9	13
153	Patient-initiated appointments compared with standard outpatient care for rheumatoid arthritis: a randomised controlled trial. <i>RMD Open</i> , 2016 , 2, e000184	5.9	7
152	Early Remission Is a Realistic Target in a Majority of Patients with DMARD-naive Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2016 , 43, 699-706	4.1	13
151	Modelling of compound combination effects and applications to efficacy and toxicity: state-of-the-art, challenges and perspectives. 2016 , 21, 225-38		108
150	Inflammatory cytokine levels, disease activity, and function of patients with rheumatoid arthritis treated with combined conventional disease-modifying antirheumatic drugs or biologics. <i>Clinical Rheumatology</i> , 2016 , 35, 1673-81	3.9	18
149	MMP-3 as a predictor for structural remission in RA patients treated with MTX monotherapy. 2016 , 18, 55		19
148	Influence of triple disease modifying anti-rheumatic drug therapy on carotid artery inflammation in drug-naive patients with recent onset of rheumatoid arthritis. <i>Rheumatology</i> , 2016 , 55, 1777-85	3.9	7
147	2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2016 , 68, 1-25	4.7	717
146	Infliximab Versus Conventional Combination Treatment and Seven-Year Work Loss in Early Rheumatoid Arthritis: Results of a Randomized Swedish Trial. <i>Arthritis Care and Research</i> , 2016 , 68, 1758-1766	4.7	6

145	2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. 2016 , 68, 1-26		1274
144	Rheumatoid Arthritis and Spondyloarthritis. 2016 , 181-215		
143	Compendium of Inflammatory Diseases. 2016 , 1145-1150		0
142	Comparative evaluation of efficacy of leflunomide versus combination of methotrexate and hydroxychloroquine in patients of rheumatoid arthritis [An Indian experience]. 2016 ,		
141	Two-year results of disease activity score (DAS)-remission-steered treatment strategies aiming at drug-free remission in early arthritis patients (the IMPROVED-study). 2016 , 18, 23		27
140	Optimal responses in disease activity scores to treatment in rheumatoid arthritis: Is a DAS28 reduction of >1.2 sufficient?. 2016 , 18, 142		5
139	Immunopathologic characterization of ultrasound-defined synovitis in rheumatoid arthritis patients in clinical remission. 2016 , 18, 74		27
138	Rheumatoid arthritis at present. 2016 , 146, 112-114		
137	Initial combination therapy versus step-up therapy in treatment to the target of remission in daily clinical practice in early rheumatoid arthritis patients: results from the DREAM registry. 2016 , 18, 60		19
136	Balancing benefits and risks of glucocorticoids in rheumatic diseases and other inflammatory joint disorders: new insights from emerging data. An expert consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). 2016 , 28, 1-16		16
135	Rheumatoid arthritis: Missed opportunities in the 2015 ACR guideline for RA treatment. 2016 , 12, 135-6		1
134	Rheumatoid arthritis management of early disease. <i>Current Opinion in Rheumatology</i> , 2016 , 28, 267-74	5.3	12
133	The role of synthetic drugs in the biologic era: therapeutic strategies for treating juvenile idiopathic arthritis. 2016 , 17, 703-14		7
132	[Rheumatoid arthritis at present]. 2016 , 146, 112-4		
131	Synovial fluid detection in intra-articular injections using a bioimpedance probe (BIP) needle-a clinical study. <i>Clinical Rheumatology</i> , 2017 , 36, 1349-1355	3.9	4
130	Comparative effectiveness of treatment options after conventional DMARDs failure in rheumatoid arthritis. <i>Rheumatology International</i> , 2017 , 37, 975-982	3.6	8
129	Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of CareRA, a randomised pragmatic open-label superiority trial. 2017 , 76, 511-520		58
128	Reductions in Radiographic Progression in Early Rheumatoid Arthritis Over Twenty-Five Years: Changing Contribution From Rheumatoid Factor in Two Multicenter UK Inception Cohorts. <i>Arthritis Care and Research</i> , 2017 , 69, 1809-1817	4.7	16

127	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. 2017 , 76, 960-977		1649
126	Alternative interpretation of data for recommendations on how to manage rheumatoid arthritis. 2017 , 76, e49		2
125	Head-to-head comparison of aggressive conventional therapy and three biological treatments and comparison of two de-escalation strategies in patients who respond to treatment: study protocol for a multicenter, randomized, open-label, blinded-assessor, phase 4 study. <i>Trials</i> , 2017 , 18, 161	2.8	11
124	Three out of four disease-modifying anti-rheumatic drug-naïve rheumatoid arthritis patients meet 28-joint Disease Activity Score remission at 12 months: results from the FIN-ERA cohort. 2017 , 46, 425-431		10
123	Meta-Regression of a Dose-Response Relationship of Methotrexate in Mono- and Combination Therapy in Disease-Modifying Antirheumatic Drug-Naive Early Rheumatoid Arthritis Patients. <i>Arthritis Care and Research</i> , 2017 , 69, 1473-1483	4.7	8
122	Biosimilars in rheumatology: A review of the evidence and their place in the treatment algorithm. <i>Rheumatology</i> , 2017 , 56, iv30-iv48	3.9	21
121	DMARD use is associated with a higher risk of dementia in patients with rheumatoid arthritis: A propensity score-matched case-control study. 2017 , 334, 217-222		24
120	Network Analysis of Drug-target Interactions: A Study on FDA-approved New Molecular Entities Between 2000 to 2015. <i>Scientific Reports</i> , 2017 , 7, 12230	4.9	26
119	Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons. <i>Rheumatology</i> , 2017 , 56, iv49-iv62	3.9	26
118	The road from development to approval: evaluating the body of evidence to confirm biosimilarity. <i>Rheumatology</i> , 2017 , 56, iv4-iv13	3.9	13
117	Similar efficacy and safety of initial COBRA-light and COBRA therapy in rheumatoid arthritis: 4-year results from the COBRA-light trial. <i>Rheumatology</i> , 2017 , 56, 1586-1596	3.9	10
116	Does addition of glucocorticoids to the initial therapy influence the later course of the disease in patients with early RA? Results from the Swiss prospective observational registry (SCQM). <i>Clinical Rheumatology</i> , 2017 , 36, 59-66	3.9	10
115	Treating rheumatoid arthritis to target: physician and patient adherence issues in contemporary rheumatoid arthritis therapy. 2017 , 23, 486-493		10
114	Do Short and Sustained Periods of American College of Rheumatology/European League Against Rheumatism Remission Predict Functional and Radiographic Outcome in Early Rheumatoid Arthritis Patients With Low Overall Damage Progression?. <i>Arthritis Care and Research</i> , 2017 , 69, 989-996	4.7	7
113	Traditional DMARDs: Methotrexate, Leflunomide, Sulfasalazine, Hydroxychloroquine, and Combination Therapies. 2017 , 958-982.e7		2
112	PER2 is downregulated by the LPS-induced inflammatory response in synoviocytes in rheumatoid arthritis and is implicated in disease susceptibility. 2017 , 16, 422-428		10
111	Developing an Agent-Based Drug Model to Investigate the Synergistic Effects of Drug Combinations. <i>Molecules</i> , 2017 , 22,	4.8	10
110	Glycoprotein YKL-40: A potential biomarker of disease activity in rheumatoid arthritis during intensive treatment with csDMARDs and infliximab. Evidence from the randomised controlled NEO-RACo trial. <i>PLoS ONE</i> , 2017 , 12, e0183294	3.7	20

109	Similar short-term clinical response to high-dose versus low-dose methotrexate in monotherapy and combination therapy in patients with rheumatoid arthritis. 2017 , 19, 258		3
108	Treatment of Rheumatoid Arthritis. 2017 , 1187-1212.e5		
107	What is the optimal target for treat-to-target strategies in rheumatoid arthritis?. <i>Current Opinion in Rheumatology</i> , 2018 , 30, 282-287	5.3	11
106	Radiographic progression in early rheumatoid arthritis patients following initial combination versus step-up treat-to-target therapy in daily clinical practice: results from the DREAM registry. <i>BMC Rheumatology</i> , 2018 , 2, 1	2.9	9
105	Evolution of clinical trials for rheumatoid arthritis and spondyloarthritis. <i>Current Opinion in Rheumatology</i> , 2018 , 30, 340-346	5.3	1
104	Drug survival and reasons for discontinuation of the first biological disease modifying antirheumatic drugs in Thai patients with rheumatoid arthritis: Analysis from the Thai Rheumatic Disease Prior Authorization registry. <i>International Journal of Rheumatic Diseases</i> , 2018 , 21, 170-178	2.3	13
103	Clinical and radiological outcomes of 5-year drug-free remission-steered treatment in patients with early arthritis: IMPROVED study. 2018 , 77, 111-118		33
102	A novel core-shell-based chromatographic method supported by ratio derivative spectrophotometry for the simultaneous determination of perindopril, indapamide, and amlodipine ternary mixtures. 2018 , 42, 1408-1419		3
101	Co-Delivery of Teriflunomide and Methotrexate from Hydroxyapatite Nanoparticles for the Treatment of Rheumatoid Arthritis: In Vitro Characterization, Pharmacodynamic and Biochemical Investigations. 2018 , 35, 201		14
100	Inadequate response to treat-to-target methotrexate therapy in patients with new-onset rheumatoid arthritis: development and validation of clinical predictors. 2018 , 77, 1261-1267		19
99	Surgical Intervention for Rheumatoid Arthritis and Complication Risks. 2018 , 15, 127-160		
98	A single bacterium restores the microbiome dysbiosis to protect bones from destruction in a rat model of rheumatoid arthritis. 2019 , 7, 107		55
97	Glucocorticoids for rheumatoid arthritis in the era of targeted therapies. 2019 , 15, 311-314		
96	The prevalence and types of discordance between physician perception and objective data from standardized measures of rheumatoid arthritis disease activity in real-world clinical practice in the US. <i>BMC Rheumatology</i> , 2019 , 3, 25	2.9	2
95	Does Triple Conventional Synthetic Disease-Modifying Antirheumatic Drug Therapy Improve upon Methotrexate as the Initial Treatment of Choice for a Rheumatoid Arthritis Patient?. <i>Rheumatic Disease Clinics of North America</i> , 2019 , 45, 315-324	2.4	1
94	The "Treat to Target" Approach to Rheumatoid Arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2019 , 45, 487-504	2.4	8
93	Remicade (infliximab): 20 years of contributions to science and medicine. 2019 , 13, 139-178		36
92	Management of rheumatoid arthritis: 2019 updated consensus recommendations from the Hong Kong Society of Rheumatology. <i>Clinical Rheumatology</i> , 2019 , 38, 3331-3350	3.9	11

91	Treat-to-target in rheumatoid arthritis - are we there yet?. 2019 , 15, 180-186		42
90	Association between C3435T polymorphism and methotrexate treatment outcomes in rheumatoid arthritis patients: a meta-analysis. 2019 , 20, 381-392		6
89	Efficacy and safety of add-on tacrolimus versus leflunomide in rheumatoid arthritis patients with inadequate response to methotrexate. <i>International Journal of Rheumatic Diseases</i> , 2019 , 22, 1115-1122 ^{2,3}		6
88	Monitoring structural modulation of redox-sensitive proteins in cells with MS-CETSA. 2019 , 24, 101168		23
87	2018 update of the APLAR recommendations for treatment of rheumatoid arthritis. <i>International Journal of Rheumatic Diseases</i> , 2019 , 22, 357-375	2.3	60
86	Team Approach: Role of Medical and Surgical Management in Rheumatoid Arthritis of the Hand and Wrist. 2019 , 7, e10		
85	Glucocorticoids for rheumatoid arthritis in the era of targeted therapies. 2019 , 15, 311-314		
84	Challenges in Implementing Treat-to-Target Strategies in Rheumatology. <i>Rheumatic Disease Clinics of North America</i> , 2019 , 45, 101-112	2.4	7
83	Automated Text Message-Enhanced Monitoring Versus Routine Monitoring in Early Rheumatoid Arthritis: A Randomized Trial. <i>Arthritis Care and Research</i> , 2020 , 72, 319-325	4.7	9
82	Treatment of Autoimmune Disease: Established Therapies. 2020 , 1415-1435		
81	Pharmacological conditioning in the treatment of recent-onset rheumatoid arthritis: a randomized controlled trial study protocol. <i>Trials</i> , 2020 , 21, 15	2.8	1
80	Recent Clinical and Preclinical Studies of Hydroxychloroquine on RNA Viruses and Chronic Diseases: A Systematic Review. <i>Molecules</i> , 2020 , 25,	4.8	2
79	Update on the treatment of nonsystemic juvenile idiopathic arthritis including treatment-to-target: is (drug-free) inactive disease already possible?. <i>Current Opinion in Rheumatology</i> , 2020 , 32, 403-413	5.3	3
78	Leflunomide monotherapy versus combination therapy with conventional synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis: a retrospective study. <i>Scientific Reports</i> , 2020 , 10, 12339	4.9	2
77	Earlier is better when treating rheumatoid arthritis: but can we detect a window of opportunity?. <i>RMD Open</i> , 2020 , 6,	5.9	5
76	[Management of early rheumatoid arthritis : Interdisciplinary guideline]. <i>Zeitschrift Fur Rheumatologie</i> , 2020 , 79, 1-38	1.9	11
75	First-year drug therapy of new-onset rheumatoid and undifferentiated arthritis: a nationwide register-based study. <i>BMC Rheumatology</i> , 2020 , 4, 34	2.9	1
74	Therapeutic Options and Cost-Effectiveness for Rheumatoid Arthritis Treatment. <i>Current Rheumatology Reports</i> , 2020 , 22, 44	4.9	6

73	Treatment strategies are more important than drugs in the management of rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2020 , 39, 1363-1368	3.9	22
72	Dose reduction and withdrawal strategy for TNF-inhibitors in psoriatic arthritis and axial spondyloarthritis: design of a pragmatic open-label, randomised, non-inferiority trial. <i>Trials</i> , 2020 , 21, 90	2.8	5
71	Combination of methotrexate and sulfasalazine is an efficacious option for axial spondyloarthritis in a resource-limited, real-world clinical setting: a prospective cohort study. <i>Clinical Rheumatology</i> , 2021 , 40, 1871-1879	3.9	2
70	Network Patterns of Herbal Combinations in Traditional Chinese Clinical Prescriptions. <i>Frontiers in Pharmacology</i> , 2020 , 11, 590824	5.6	6
69	A patient-centered knowledge translation tool for treat-to-target strategy in rheumatoid arthritis: Patient and rheumatologist perspectives. <i>International Journal of Rheumatic Diseases</i> , 2021 , 24, 355-363 ^{2,3}	2.3	1
68	Treat-to-Target Strategies in Rheumatoid Arthritis: a Systematic Review and Cost-Effectiveness Analysis. <i>SN Comprehensive Clinical Medicine</i> , 2021 , 3, 838-854	2.7	0
67	Hydroxychloroquine in systemic and autoimmune diseases: Where are we now?. <i>Joint Bone Spine</i> , 2021 , 88, 105143	2.9	4
66	Combination Therapy With Tofacitinib and IL-12/23, IL-23, or IL-17A Inhibition for the Treatment of Refractory Psoriatic Arthritis: A Case Series. <i>Journal of Clinical Rheumatology</i> , 2021 ,	1.1	0
65	Intensive therapy for moderate established rheumatoid arthritis: the TITRATE research programme. <i>Programme Grants for Applied Research</i> , 2021 , 9, 1-186	1.5	0
64	Comparison between leflunomide and sulfasalazine based triple therapy in methotrexate refractory rheumatoid arthritis: an open-label, non-inferiority randomized controlled trial. <i>Rheumatology International</i> , 2021 , 1	3.6	1
63	Estimating the Impact of Humanizing Customer Service Chatbots. <i>Information Systems Research</i> , 2021 , 32, 736-751	3.8	14
62	Effect of subcutaneous high-dose methotrexate treatment on the management of rheumatoid arthritis. <i>Cukurova Medical Journal</i> , 2021 , 46, 1150-1159	0.1	
61	Hydroxychloroquine dans les maladies systémiques et auto-immunes: où en sommes-nous?. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2021 , 88, 346-353	0.1	
60	Editorial Commentary: If Individual Treatments Are Potentiated, Multimodal Therapy Including Cells and Platelet-Rich Plasma May Beneficially Treat Cartilage Degeneration and Arthritis. <i>Arthroscopy - Journal of Arthroscopic and Related Surgery</i> , 2021 , 37, 3138-3139	5.4	
59	Management of the patient with rheumatoid arthritis. 2006 , 97-109		1
58	Cinnarizine: A Contemporary Review. <i>Indian Journal of Otolaryngology and Head and Neck Surgery</i> , 2019 , 71, 1060-1068	0.6	9
57	Treatment of Rheumatoid Arthritis. 2009 , 1119-1143		4
56	Traditional DMARDs: Methotrexate, Leflunomide, Sulfasalazine, Hydroxychloroquine, and Combination Therapies. 2013 , 917-940.e6		2

55	Treatment of Rheumatoid Arthritis. 2013 , 1137-1160.e4		2
54	Trigger-responsive engineered-nanocarriers and image-guided theranostics for rheumatoid arthritis. <i>Nanoscale</i> , 2020 , 12, 12673-12697	7.7	11
53	Effect of combination therapy on joint destruction in rheumatoid arthritis: a network meta-analysis of randomized controlled trials. <i>PLoS ONE</i> , 2014 , 9, e106408	3.7	25
52	Efficacy and Safety of Rituximab in Biologic-Naive Patients with Rheumatoid Arthritis vs Anti-Tnf Therapy Failure. <i>Open Rheumatology Journal</i> , 2013 , 7, 81-6	0.2	1
51	Infliximab in the treatment of rheumatoid arthritis. <i>Aging Health</i> , 2006 , 2, 19-33		1
50	Safety and efficacy of etanercept in the elderly. <i>Aging Health</i> , 2006 , 2, 189-197		2
49	Development and deployment of antigen arrays for investigation of B-cell fine specificity in autoimmune disease. <i>Frontiers in Bioscience - Elite</i> , 2012 , 4, 320-30	1.6	9
48	The clinical effectiveness and cost-effectiveness of treat-to-target strategies in rheumatoid arthritis: a systematic review and cost-effectiveness analysis. <i>Health Technology Assessment</i> , 2017 , 21, 1-258	4.4	27
47	New guidelines for treatment of rheumatoid arthritis. <i>Interni Medicina Pro Praxi</i> , 2018 , 20, 62-67	0	0
46	TNF- β inhibition: The Need for a Tumor Necrosis Factor Thermostat. <i>Mayo Clinic Proceedings</i> , 2001 , 76, 573-575	6.4	9
45	Defining Remission of Korean Patients with Rheumatoid Arthritis. <i>The Journal of the Korean Rheumatism Association</i> , 2008 , 15, 204		1
44	Is non-biological treatment of rheumatoid arthritis as good as biologics?. <i>World Journal of Orthopedics</i> , 2015 , 6, 278-83	2.2	9
43	Methodology of combination trials. 2002 , 27-33		
42	Kombination von Basistherapeutika. 2002 , 36-39		
41	TNF- β inhibition in practical management of rheumatoid arthritis. 2004 , 99-120		
40	Autoimmunity [Rheumatoid Arthritis. 2005 , 481-493		
39	Combination therapy. 2005 , 293-318		
38	Pharmacogenetics in Rheumatology. 2006 , 189-208		

- 37 Expanding quantitative assessment of rheumatoid arthritis in usual care. *Future Rheumatology*, **2007**, 2, 469-473
- 36 RHEUMATOID ARTHRITIS 714.0. **2008**, 169-171
- 35 Early (Rheumatoid) Arthritis. **2009**, 73-81
- 34 RHEUMATOID ARTHRITIS. **2009**, 1025-1038
- 33 Methotrexate, Leflunomide, Sulfasalazine, Hydroxychloroquine, and Combination Therapies. **2009**, 883-907 ○
- 32 Other Traditional Disease-Modifying Antirheumatic Drugs: Monotherapy and Combination Therapy. **2009**, 325-336
- 31 Rheumatoid Arthritis. **2009**, 1-13
- 30 The efficacy of disease modifying anti-rheumatic drugs in rheumatoid arthritis in local patients of Karachi. *Pakistan Journal of Biological Sciences*, **2009**, 12, 339-45 0.8 2
- 29 Articular ultrasonography in rheumatoid arthritis. *International Journal of Clinical Rheumatology*, **2009**, 4, 583-595 1.5
- 28 BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy. *Rheumatology*, **2010**, 3.9 ○
- 27 Immunosuppressives (chlorambucil, cyclosporine, cyclophosphamide [Cytosan], azathioprine [Imuran], mofetil, tacrolimus). **2011**, 529-538.e2
- 26 Evaluation and management of early inflammatory polyarthritis. **2011**, 935-940.e3
- 25 Parenteral gold, antimalarials, and sulfasalazine. **2011**, 505-507
- 24 Management of rheumatoid arthritis. **2011**, 955-963.e2
- 23 Early Arthritis. *Open Journal of Rheumatology and Autoimmune Diseases*, **2012**, 02, 94-101 0.2
- 22 Rheumatology and Musculoskeletal Problems. **2012**, 648-689
- 21 Entzündliche Gelenkerkrankungen. **2012**, 195-399
- 20 Skeleton, Inflammatory Diseases of. **2014**,

19	Immunotherapy. 2015 , 195-232		
18	Compendium of Inflammatory Diseases. 2016 , 1159-1168		
17	Relation between treatment duration and temperature factors in rheumatoid arthritis.		
16	Mean to long-term clinical and radiological results of unlinked total elbow arthroplasty. <i>MOJ Orthopedics & Rheumatology</i> , 2019 , 11,	2	
15	First-year drug therapy of new-onset rheumatoid and undifferentiated arthritis: A nationwide register-based study..		
14	Symptomization of Rheumatoid Arthritis in Patients on Pathological Examination: A Case Study. 2020 ,		0
13	First-year drug therapy of new-onset rheumatoid and undifferentiated arthritis: A nationwide register-based study..		
12	Historical and Current Perspectives on Management of Osteoarthritis and Rheumatoid Arthritis. 2008 , 5-36		1
11	Treatment of early rheumatoid arthritis. <i>Therapy: Open Access in Clinical Medicine</i> , 2005 , 2, 659-668		
10	Predictive value of antibodies to cyclic citrullinated peptide in patients with very early inflammatory arthritis. <i>Journal of Rheumatology</i> , 2005 , 32, 231-8	4.1	95
9	Can rheumatoid arthritis ever cease to exist: a review of various therapeutic modalities to maintain drug-free remission?. <i>American Journal of Translational Research (discontinued)</i> , 2017 , 9, 3758-3775	3	3
8	Rheumatoid Arthritis disease activity assessment in routine care: performance of the most widely used composite disease activity indices and patient-reported outcome measures. <i>Acta Biomedica</i> , 2021 , 92, e2021238	3.2	0
7	Disease-Modifying Antirheumatic Drugs and Risk of Parkinson Disease: Nested Case-Control Study of People With Rheumatoid Arthritis.. <i>Neurology</i> , 2022 ,	6.5	1
6	Defining the Optimal Strategies for Achieving Drug-Free Remission in Rheumatoid Arthritis: A Narrative Review.. <i>Healthcare (Switzerland)</i> , 2021 , 9,	3.4	1
5	Economic evaluation of infliximab, synthetic triple therapy and methotrexate in the treatment of newly diagnosed juvenile idiopathic arthritis. 2022 , 20,		0
4	Joint Replacement Surgery in Patients with Rheumatoid Arthritis in South Korea: Analysis of a Large National Database. 14,		0
3	Frñe rheumatoide Arthritis. 2022 , 164, 24-31		0
2	Rheumatoid Arthritis. 2016 , 1-9		0

1 Assessment of Rheumatoid Arthritis in Clinical Care. **2010**, 25, 1-11

o